Safety and Tolerability Study of VTS-270 in Pediatric Participants With Niemann-Pick Type C (NPC) Disease
Status:
Withdrawn
Trial end date:
2022-10-30
Target enrollment:
Participant gender:
Summary
This is a Phase-2, multicenter, multiple dose, open-label, 2-part evaluation study which will
primarily assess the safety and tolerability of VTS-270 (2-hydroxypropyl beta-cyclodextrin
[HP-β-CD]) in pediatric participants with age <4 years.
Phase:
Phase 2
Details
Lead Sponsor:
Vtesse, Inc., a Mallinckrodt Pharmaceuticals Company Vtesse, LLC, a Mallinckrodt Pharmaceuticals Company